114 related articles for article (PubMed ID: 31130340)
1. Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database.
Roy S; Morgan SC
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):630-636. PubMed ID: 31130340
[TBL] [Abstract][Full Text] [Related]
2. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
3. Competing risk of the specific mortality among Asian-American patients with prostate cancer: a surveillance, epidemiology, and end results analysis.
Wu D; Yang Y; Jiang M; Yao R
BMC Urol; 2022 Mar; 22(1):42. PubMed ID: 35331219
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
6. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
[TBL] [Abstract][Full Text] [Related]
7. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of Gleason scores in metastatic prostate cancer.
Rusthoven CG; Carlson JA; Waxweiler TV; Yeh N; Raben D; Flaig TW; Kavanagh BD
Urol Oncol; 2014 Jul; 32(5):707-13. PubMed ID: 24629494
[TBL] [Abstract][Full Text] [Related]
9. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities.
Dee EC; Nezolosky MD; Chipidza FE; Arega MA; Butler SS; Sha ST; Mahal BA; Nguyen PL; Yang DD; Muralidhar V
Prostate; 2020 Sep; 80(13):1128-1133. PubMed ID: 32659024
[TBL] [Abstract][Full Text] [Related]
11. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study.
Rusthoven CG; Carlson JA; Waxweiler TV; Raben D; Dewitt PE; Crawford ED; Maroni PD; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1064-73. PubMed ID: 24661660
[TBL] [Abstract][Full Text] [Related]
12. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer.
Rusthoven CG; Waxweiler TV; DeWitt PE; Flaig TW; Raben D; Kavanagh BD
Urol Oncol; 2015 Feb; 33(2):71.e11-9. PubMed ID: 25151595
[TBL] [Abstract][Full Text] [Related]
13. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
[TBL] [Abstract][Full Text] [Related]
14. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
[TBL] [Abstract][Full Text] [Related]
15. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
16. Is pelvic lymph node dissection necessary in patients with biopsy proven Gleason 6 prostate cancer? - analysis of the SEER database.
Daugherty M; Sedaghatpour D; Bratslavsky G; Shapiro O
Can J Urol; 2018 Aug; 25(4):9414-9420. PubMed ID: 30125522
[TBL] [Abstract][Full Text] [Related]
17. Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis.
Muralidhar V; Mahal BA; Nguyen PL
Radiat Oncol; 2015 Jul; 10():155. PubMed ID: 26220664
[TBL] [Abstract][Full Text] [Related]
18. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
19. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
Preisser F; Marchioni M; Nazzani S; Bandini M; Tian Z; Saad F; Pompe RS; Briganti A; Budäus L; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol Oncol; 2018 Jun; 1(2):160-168. PubMed ID: 31100241
[TBL] [Abstract][Full Text] [Related]
20. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]